Abstract:
Hepatitis C virus (HCV) is an RNA virus with seven primary genotypes. It is highly prevalent in Pakistan, especially
genotype 3. HCV infection can progress to a chronic state with further complications. Direct-acting antiviral agents (DAAV)
were introduced in 2014 as a treatment option, some of which include Sofosbuvir (SOF), Daclatasvir (DCV), Velpatasvir
(VEL) and Ribavirin (RV). This meta-analysis was performed to outline the treatment response and efficacy of DAAV in
HCV infected patients.
We systematically searched PubMed, Web of Science, MEDLINE, and Google Scholar for studies from January 2019 to
December 2023. The studies selected met the criteria of patients having chronic HCV infection (genotype 3) and either
compensated cirrhosis or decompensated chronic liver disease. Treatment regimens with DAAV specifically were included.
The primary outcomes [sustained viral response (SVR), rapid virological response (RVR), end-of-treatment response (ETR)]
were highlighted to assess treatment response.
The studies proved that the use of direct-acting antiviral agents in different combinations was very effective against HCV
infection with minimal side-effects
